146 related articles for article (PubMed ID: 32324779)
1. Associations among smoking, MGMT hypermethylation, TP53-mutations, and relapse in head and neck squamous cell carcinoma.
Matsuda S; Mafune A; Kohda N; Hama T; Urashima M
PLoS One; 2020; 15(4):e0231932. PubMed ID: 32324779
[TBL] [Abstract][Full Text] [Related]
2. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
[TBL] [Abstract][Full Text] [Related]
3. MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.
Groenendijk FH; Taal W; Dubbink HJ; Haarloo CR; Kouwenhoven MC; van den Bent MJ; Kros JM; Dinjens WN
J Neurooncol; 2011 Feb; 101(3):405-17. PubMed ID: 20593220
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
5. O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma.
Zuo C; Ai L; Ratliff P; Suen JY; Hanna E; Brent TP; Fan CY
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):967-75. PubMed ID: 15184253
[TBL] [Abstract][Full Text] [Related]
6. MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases.
Nagy E; Gajjar KB; Patel II; Taylor S; Martin-Hirsch PL; Stringfellow HF; Martin FL; Phillips DH
Br J Cancer; 2014 Jun; 110(12):2874-80. PubMed ID: 24853176
[TBL] [Abstract][Full Text] [Related]
7. Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head and neck carcinoma.
Mafune A; Hama T; Suda T; Suzuki Y; Ikegami M; Sakanashi C; Imai S; Nakashima A; Yokoo T; Wada K; Kojima H; Urashima M
BMC Cancer; 2015 Mar; 15():205. PubMed ID: 25886176
[TBL] [Abstract][Full Text] [Related]
8. Promoter methylation of MGMT gene in serum of patients with esophageal squamous cell carcinoma in North East India.
Das M; Sharma SK; Sekhon GS; Saikia BJ; Mahanta J; Phukan RK
Asian Pac J Cancer Prev; 2014; 15(22):9955-60. PubMed ID: 25520135
[TBL] [Abstract][Full Text] [Related]
9. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.
de Vogel S; Weijenberg MP; Herman JG; Wouters KA; de Goeij AF; van den Brandt PA; de Bruïne AP; van Engeland M
Ann Oncol; 2009 Jul; 20(7):1216-22. PubMed ID: 19164452
[TBL] [Abstract][Full Text] [Related]
10. Expression levels of miR-34-family microRNAs are associated with TP53 mutation status in head and neck squamous cell carcinoma.
Metheetrairut C; Chotigavanich C; Amornpichetkul K; Keskool P; Ongard S; Metheetrairut C
Eur Arch Otorhinolaryngol; 2019 Feb; 276(2):521-533. PubMed ID: 30515607
[TBL] [Abstract][Full Text] [Related]
11. Methylation of MGMT and ADAMTS14 in normal colon mucosa: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans.
Alonso S; Dai Y; Yamashita K; Horiuchi S; Dai T; Matsunaga A; Sánchez-Muñoz R; Bilbao-Sieyro C; Díaz-Chico JC; Chernov AV; Strongin AY; Perucho M
Oncotarget; 2015 Feb; 6(5):3420-31. PubMed ID: 25638164
[TBL] [Abstract][Full Text] [Related]
12. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
13. Alteration in the expression of MGMT and RUNX3 due to non-CpG promoter methylation and their correlation with different risk factors in esophageal cancer patients.
Saikia S; Rehman AU; Barooah P; Sarmah P; Bhattacharyya M; Deka M; Deka M; Goswami B; Husain SA; Medhi S
Tumour Biol; 2017 May; 39(5):1010428317701630. PubMed ID: 28468586
[TBL] [Abstract][Full Text] [Related]
14. KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients.
Bagci B; Sari M; Karadayi K; Turan M; Ozdemir O; Bagci G
Cancer Biomark; 2016 Jun; 17(2):133-43. PubMed ID: 27540971
[TBL] [Abstract][Full Text] [Related]
15. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
Shamsara J; Sharif S; Afsharnezhad S; Lotfi M; Raziee HR; Ghaffarzadegan K; Moradi A; Rahighi S; Behravan J
Cancer Invest; 2009 Oct; 27(8):825-9. PubMed ID: 19544111
[TBL] [Abstract][Full Text] [Related]
16. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer.
Sun W; Zaboli D; Wang H; Liu Y; Arnaoutakis D; Khan T; Khan Z; Koch WM; Califano JA
Clin Cancer Res; 2012 Feb; 18(4):1082-91. PubMed ID: 22228635
[TBL] [Abstract][Full Text] [Related]
17. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
18. Aberrant gene promoter methylation of E-cadherin, p16
Burassakarn A; Pientong C; Sunthamala N; Chuerduangphui J; Vatanasapt P; Patarapadungkit N; Kongyingyoes B; Ekalaksananan T
Med Oncol; 2017 Jul; 34(7):128. PubMed ID: 28573642
[TBL] [Abstract][Full Text] [Related]
19. MGMT hypermethylation and BCL-2 overexpression associated with superficial bladder cancer and recurrence.
Jahed M; Ebadi N; Mivehchi M; Majidizadeh T; Shahshanipour M; Asgari M; Ghadakzadeh S; Hosseini SA
Cancer Biomark; 2016 Mar; 16(4):627-32. PubMed ID: 27002765
[TBL] [Abstract][Full Text] [Related]
20. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
Li X; Wei J; Liu Y; Li P; Fan L; Wang Y; Li M; Zhao D; Yu Z; Ye J; Guo Y; Yan Q; Guo S; Wang Z
Sci Rep; 2017 Oct; 7(1):13038. PubMed ID: 29026176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
